Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun 30;13(6):1061-1063.
doi: 10.21037/tau-23-630. Epub 2024 May 24.

Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer

Olutiwa A Akinsola  1 , Ruchika Talwar  1 , Avi Baskin  1 , Amy N Luckenbaugh  1 , Bashir Al Hussein Al Awamlh  2
Affiliations
Editorial

Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer

Olutiwa A Akinsola et al. Transl Androl Urol. .
No abstract available

Keywords: Bacillus Calmette-Guérin (BCG); atezolizumab; high-risk non-muscle invasive bladder cancer (high-risk NMIBC); immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-630/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Flaig TW, Spiess PE, Abern M, et al. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 2022;20:866-78. 10.6004/jnccn.2022.0041 - DOI - PubMed
    1. Al Hussein Al Awamlh B, Talwar R, Luckenbaugh A, et al. An Update on the Supply and Production of Bacille Calmette-Guérin. (n.d.). ASCO Daily News. Published January 18, 2023. Accessed November 26, 2023. Available online: https://dailynews.ascopubs.org/do/update-supply-and-production-bacille-c...
    1. Black PC, Tangen CM, Singh P, et al. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol 2023;84:536-44. 10.1016/j.eururo.2023.08.004 - DOI - PMC - PubMed
    1. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919-30. Erratum in: Lancet Oncol 2021;22:e347. 10.1016/S1470-2045(21)00147-9 - DOI - PubMed
    1. FDA, CDER, & Mccrayk. (2018). BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry. Available online: https://www.fda.gov/media/101468/download

LinkOut - more resources